Clinical Therapy Using iPSCs: Hopes and Challenges

Genomics, Proteomics and Bioinformatics

Volumn 11, Issue 5, 2013, Pages 294-298

  Lu, Xiao ^a   Zhao, Tongbiao ^a  

^a INSTITUTE OF ZOOLOGY   (China)

Author keywords

Disease modeling; Immunogenicity; IPSC; Regenerative medicine; Tumorigenicity

Indexed keywords

KRUPPEL LIKE FACTOR 4; OCTAMER TRANSCRIPTION FACTOR 4; PROTEIN P53; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NANOG;

CANCER RISK; CARCINOGENICITY; CELL DIFFERENTIATION; CELL RENEWAL; CELL THERAPY; EMBRYONIC STEM CELL; GENE AMPLIFICATION; GENE DELETION; GENOMIC INSTABILITY; GERM LAYER; HUMAN; IMMUNOGENICITY; NONHUMAN; PLURIPOTENT STEM CELL; PROTEIN EXPRESSION; REGENERATIVE MEDICINE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC CELL; STEM CELL TRANSPLANTATION;

DISEASE MODELING; IMMUNOGENICITY; IPSC; REGENERATIVE MEDICINE; TUMORIGENICITY;

ANIMALS; CELL- AND TISSUE-BASED THERAPY; GENOMIC INSTABILITY; HUMANS; IMMUNOGENETIC PROCESSES; INDUCED PLURIPOTENT STEM CELLS; NEOPLASMS; REGENERATION;

EID: 84886407915     PISSN: 16720229     EISSN: 22103244     Source Type: Journal    
DOI: 10.1016/j.gpb.2013.09.002     Document Type: Review

References (69)

1. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126:663-676.
2. Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131:861-872.
3. Wernig M., Meissner A., Foreman R., Brambrink T., Ku M., Hochedlinger K., et al. In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature 2007, 448:318-324.
4. Lowry W.E., Richter L., Yachechko R., Pyle A.D., Tchieu J., Sridharan R., et al. Generation of human induced pluripotent stem cells from dermal fibroblasts. Proc Natl Acad Sci U S A 2008, 105:2883-2888.
5. Park I.H., Zhao R., West J.A., Yabuuchi A., Huo H., Ince T.A., et al. Reprogramming of human somatic cells to pluripotency with defined factors. Nature 2008, 451:141-146.
6. Yu J., Vodyanik M.A., Smuga-Otto K., Antosiewicz-Bourget J., Frane J.L., Tian S., et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007, 318:1917-1920.
7. Okita K., Ichisaka T., Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature 2007, 448:313-317.
8. Boland M.J., Hazen J.L., Nazor K.L., Rodriguez A.R., Gifford W., Martin G., et al. Adult mice generated from induced pluripotent stem cells. Nature 2009, 461:91-94.
9. Kang L., Wang J., Zhang Y., Kou Z., Gao S. IPS cells can support full-term development of tetraploid blastocyst-complemented embryos. Cell Stem Cell 2009, 5:135-138.
10. Zhao X.Y., Li W., Lv Z., Liu L., Tong M., Hai T., et al. IPS cells produce viable mice through tetraploid complementation. Nature 2009, 461:86-90.
11. Han J., Sidhu K.S. Current concepts in reprogramming somatic cells to pluripotent state. Curr Stem Cell Res Ther 2008, 3:66-74.
12. Wu S.M., Hochedlinger K. Harnessing the potential of induced pluripotent stem cells for regenerative medicine. Nat Cell Biol 2011, 13:497-505.
13. Buganim Y., Faddah D.A., Cheng A.W., Itskovich E., Markoulaki S., Ganz K., et al. Single-cell expression analyses during cellular reprogramming reveal an early stochastic and a late hierarchic phase. Cell 2012, 150:1209-1222.
14. Soufi A., Donahue G., Zaret K.S. Facilitators and impediments of the pluripotency reprogramming factors' initial engagement with the genome. Cell 2012, 151:994-1004.
15. Ebert A.D., Yu J., Rose F.F., Mattis V.B., Lorson C.L., Thomson J.A., et al. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 2009, 457:277-280.
16. Marchetto M.C., Carromeu C., Acab A., Yu D., Yeo G.W., Mu Y., et al. A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. Cell 2010, 143:527-539.
17. Liu G.H., Barkho B.Z., Ruiz S., Diep D., Qu J., Yang S.L., et al. Recapitulation of premature ageing with iPSCs from Hutchinson-Gilford progeria syndrome. Nature 2011, 472:221-225.
18. Zhang J., Lian Q., Zhu G., Zhou F., Sui L., Tan C., et al. A human iPSC model of Hutchinson Gilford Progeria reveals vascular smooth muscle and mesenchymal stem cell defects. Cell Stem Cell 2011, 8:31-45.
19. Liu G.H., Qu J., Suzuki K., Nivet E., Li M., Montserrat N., et al. Progressive degeneration of human neural stem cells caused by pathogenic LRRK2. Nature 2012, 491:603-607.
20. Moretti A., Bellin M., Welling A., Jung C.B., Lam J.T., Bott-Flugel L., et al. Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N Engl J Med 2010, 363:1397-1409.
21. Kim C., Wong J., Wen J., Wang S., Wang C., Spiering S., et al. Studying arrhythmogenic right ventricular dysplasia with patient-specific iPSCs. Nature 2013, 494:105-110.
22. Schwartz R.E., Trehan K., Andrus L., Sheahan T.P., Ploss A., Duncan S.A., et al. Modeling hepatitis C virus infection using human induced pluripotent stem cells. Proc Natl Acad Sci U S A 2012, 109:2544-2548.
23. Trounson A., Shepard K.A., DeWitt N.D. Human disease modeling with induced pluripotent stem cells. Curr Opin Genet Dev 2012, 22:509-516.
24. Si-Tayeb K., Duclos-Vallee J.C., Petit M.A. Hepatocyte-like cells differentiated from human induced pluripotent stem cells (iHLCs) are permissive to hepatitis C virus (HCV) infection: HCV study gets personal. J Hepatol 2012, 57:689-691.
25. Sourisseau M., Goldman O., He W., Gori J.L., Kiem H.P., Gouon-Evans V., et al. Hepatic cells derived from induced pluripotent stem cells of pigtail macaques support hepatitis C virus infection. Gastroenterology 2013, PII: S0016-5085(13)01077-9.
26. Spence J.R., Mayhew C.N., Rankin S.A., Kuhar M.F., Vallance J.E., Tolle K., et al. Directed differentiation of human pluripotent stem cells into intestinal tissue in vitro. Nature 2011, 470:105-109.
27. Takebe T., Sekine K., Enomura M., Koike H., Kimura M., Ogaeri T., et al. Vascularized and functional human liver from an iPSC-derived organ bud transplant. Nature 2013, 499:481-484.
28. Hanna J., Wernig M., Markoulaki S., Sun C.W., Meissner A., Cassady J.P., et al. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 2007, 318:1920-1923.
29. Lu T.Y., Lin B., Kim J., Sullivan M., Tobita K., Salama G., et al. Repopulation of decellularized mouse heart with human induced pluripotent stem cell-derived cardiovascular progenitor cells. Nat Commun 2013, 4:2307.
30. Schwartz S.D., Hubschman J.P., Heilwell G., Franco-Cardenas V., Pan C.K., Ostrick R.M., et al. Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet 2012, 379:713-720.
31. Tong M., Lv Z., Liu L., Zhu H., Zheng Q.Y., Zhao X.Y., et al. Mice generated from tetraploid complementation competent iPS cells show similar developmental features as those from ES cells but are prone to tumorigenesis. Cell Res 2011, 21:1634-1637.
32. Kaji K., Norrby K., Paca A., Mileikovsky M., Mohseni P., Woltjen K. Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature 2009, 458:771-775.
33. Woltjen K., Michael I.P., Mohseni P., Desai R., Mileikovsky M., Hamalainen R., et al. PiggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature 2009, 458:766-770.
34. Okita K., Nakagawa M., Hyenjong H., Ichisaka T., Yamanaka S. Generation of mouse induced pluripotent stem cells without viral vectors. Science 2008, 322:949-953.
35. Stadtfeld M., Nagaya M., Utikal J., Weir G., Hochedlinger K. Induced pluripotent stem cells generated without viral integration. Science 2008, 322:945-949.
36. Gonzalez F., Barragan Monasterio M., Tiscornia G., Montserrat Pulido N., Vassena R., Batlle Morera L., et al. Generation of mouse-induced pluripotent stem cells by transient expression of a single nonviral polycistronic vector. Proc Natl Acad Sci U S A 2009, 106:8918-8922.
37. Yu J., Hu K., Smuga-Otto K., Tian S., Stewart R., Slukvin I.I., et al. Human induced pluripotent stem cells free of vector and transgene sequences. Science 2009, 324:797-801.
38. Zhou W., Freed C.R. Adenoviral gene delivery can reprogram human fibroblasts to induced pluripotent stem cells. Stem Cells 2009, 27:2667-2674.
39. Wang Y., Chen J., Hu J.L., Wei X.X., Qin D., Gao J., et al. Reprogramming of mouse and human somatic cells by high-performance engineered factors. EMBO Rep 2011, 12:373-378.
40. Zhao T., Zhang Z.N., Rong Z., Xu Y. Immunogenicity of induced pluripotent stem cells. Nature 2011, 474:212-215.
41. Kim D., Kim C.H., Moon J.I., Chung Y.G., Chang M.Y., Han B.S., et al. Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell 2009, 4:472-476.
42. Zhou H., Wu S., Joo J.Y., Zhu S., Han D.W., Lin T., et al. Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell 2009, 4:381-384.
43. Hou P., Li Y., Zhang X., Liu C., Guan J., Li H., et al. Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds. Science 2013, 341:651-654.
44. Gidekel S., Pizov G., Bergman Y., Pikarsky E. Oct-3/4 is a dose-dependent oncogenic fate determinant. Cancer Cell 2003, 4:361-370.
45. Hochedlinger K., Yamada Y., Beard C., Jaenisch R. Ectopic expression of Oct-4 blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues. Cell 2005, 121:465-477.
46. Levings P.P., McGarry S.V., Currie T.P., Nickerson D.M., McClellan S., Ghivizzani S.C., et al. Expression of an exogenous human Oct-4 promoter identifies tumor-initiating cells in osteosarcoma. Cancer Res 2009, 69:5648-5655.
47. Bass A.J., Watanabe H., Mermel C.H., Yu S., Perner S., Verhaak R.G., et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 2009, 41:1238-1242.
48. Rowland B.D., Peeper D.S. KLF4, p21 and context-dependent opposing forces in cancer. Nat Rev Cancer 2006, 6:11-23.
49. Pelengaris S., Khan M., Evan G. C-MYC: more than just a matter of life and death. Nat Rev Cancer 2002, 2:764-776.
50. Hart A.H., Hartley L., Parker K., Ibrahim M., Looijenga L.H., Pauchnik M., et al. The pluripotency homeobox gene NANOG is expressed in human germ cell tumors. Cancer 2005, 104:2092-2098.
51. Piestun D., Kochupurakkal B.S., Jacob-Hirsch J., Zeligson S., Koudritsky M., Domany E., et al. Nanog transforms NIH3T3 cells and targets cell-type restricted genes. Biochem Biophys Res Commun 2006, 343:279-285.
52. Lu X., Mazur S.J., Lin T., Appella E., Xu Y. The pluripotency factor nanog promotes breast cancer tumorigenesis and metastasis. Oncogene 2013, 10.1038/onc.2013.209.
53. Banito A., Gil J. Induced pluripotent stem cells and senescence: learning the biology to improve the technology. EMBO Rep 2010, 11:353-359.
54. Araki R., Uda M., Hoki Y., Sunayama M., Nakamura M., Ando S., et al. Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells. Nature 2013, 494:100-104.
55. Guha P., Morgan J.W., Mostoslavsky G., Rodrigues N.P., Boyd A.S. Lack of immune response to differentiated cells derived from syngeneic induced pluripotent stem cells. Cell Stem Cell 2013, 12:407-412.
56. Chin M.H., Mason M.J., Xie W., Volinia S., Singer M., Peterson C., et al. Induced pluripotent stem cells and embryonic stem cells are distinguished by gene expression signatures. Cell Stem Cell 2009, 5:111-123.
57. Pasi C.E., Dereli-Oz A., Negrini S., Friedli M., Fragola G., Lombardo A., et al. Genomic instability in induced stem cells. Cell Death Differ 2011, 18:745-753.
58. Laurent L.C., Ulitsky I., Slavin I., Tran H., Schork A., Morey R., et al. Dynamic changes in the copy number of pluripotency and cell proliferation genes in human ESCs and iPSCs during reprogramming and time in culture. Cell Stem Cell 2011, 8:106-118.
59. Hussein S.M., Batada N.N., Vuoristo S., Ching R.W., Autio R., Narva E., et al. Copy number variation and selection during reprogramming to pluripotency. Nature 2011, 471:58-62.
60. Gore A., Li Z., Fung H.L., Young J.E., Agarwal S., Antosiewicz-Bourget J., et al. Somatic coding mutations in human induced pluripotent stem cells. Nature 2011, 471:63-67.
61. Stiewe T. The p53 family in differentiation and tumorigenesis. Nat Rev Cancer 2007, 7:165-168.
62. Vousden K.H., Lane D.P. P53 in health and disease. Nat Rev Mol Cell Biol 2007, 8:275-283.
63. Meek D.W. Tumour suppression by p53: a role for the DNA damage response?. Nat Rev Cancer 2009, 9:714-723.
64. Zhao Y., Yin X., Qin H., Zhu F., Liu H., Yang W., et al. Two supporting factors greatly improve the efficiency of human iPSC generation. Cell Stem Cell 2008, 3:475-479.
65. Hong H., Takahashi K., Ichisaka T., Aoi T., Kanagawa O., Nakagawa M., et al. Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature 2009, 460:1132-1135.
66. Kawamura T., Suzuki J., Wang Y.V., Menendez S., Morera L.B., Raya A., et al. Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature 2009, 460:1140-1144.
67. Li H., Collado M., Villasante A., Strati K., Ortega S., Canamero M., et al. The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature 2009, 460:1136-1139.
68. Marion R.M., Strati K., Li H., Murga M., Blanco R., Ortega S., et al. A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature 2009, 460:1149-1153.
69. Utikal J., Polo J.M., Stadtfeld M., Maherali N., Kulalert W., Walsh R.M., et al. Immortalization eliminates a roadblock during cellular reprogramming into iPS cells. Nature 2009, 460:1145-1148.